DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences enters its Phase I clinical trial in the United States on March 15.
DC402234, a peptidomimetic compound, was designed and synthesized through analyzing the crystal structure of the coronaviruses Mpro.
Researchers found that DC402234 exhibits effective inhibitory activity against SARS-CoV-2 Mpro with IC50 values of 0.053 ± 0.005 μM, and vibrant anti-SARS-CoV-2-infection activity in cell culture (EC50 values of 0.42 ± 0.08 μM).
Furthermore, DC402234 shows good pharmacokinetic properties and safety in vivo.
The drug candidate DC402234 owns China's independent intellectual property rights.
The drug candidate completed a systematic preclinical study after being licensed, and was then submitted to the Chinese National Medical Products Administration and the U.S. Food and Drug Administration for clinical trials in July, 2020.
Prof. Gregory Tarcey, main investigator of DC402234 from the US Frontage Phase I Research Center, will carry out the Phase I clinical trial in the United States.
The study was led by Professors LIU Hong, XU Yechun and JIANG Hualiang’s teams from SIMM, together with Professors YANG Haitao, RAO Zihe’s team from Shanghai Institute for Advanced Immunochemical Studies of ShanghaiTech University, and Professors ZHANG Lei-Ke, XIAO Gengfu’s team from Wuhan Institute of Virology of CAS.
Results of this research was published online in Science in June, 2020.
The effective anti-SARS-CoV-2 in vitro activity of DC402234 will bring more research prospects. However, there is still a long way to go for DC402234 as a new drug, from entering the human clinical trial stage to final application and marketing in the future.
A research team led by Prof. ZHENG Yongtang from Kunming Institute of Zoology of the Chinese Academy of Sciences, collaborating with Prof. YANG Shengyong and Prof. LEI Jian from West China Hospital of Sichuan University, developed anti-SARS-CoV-2 inhibitors. The finding was published in Science.
On September 30, 2017, Prof. LIU Wenjun's lab at the Institute of Microbiology of Chinese Academy of Sciences made a joint declaration with Qingdao Vland Biological Products Co., Ltd., Qingdao National Animal Protection Engineering Technology Research Center Co., Ltd., etc., and have received the clinical approval. The clinical preparation was that the recombinant plasmid of chicken α-interferon gene was expressed by fermentation into Escherichia coli, and the recombinant protein was taken by drinking water, which had good clinical effect on the prevention and treatment of H9 subtype avian influenza infection.
86-10-68597521 (day)
86-10-68597289 (night)
86-10-68511095 (day)
86-10-68512458 (night)
cas_en@cas.cn
52 Sanlihe Rd., Xicheng District,
Beijing, China (100864)
Copyright © 2002 - Chinese Academy of Sciences
